U.S. markets closed

Silk Road Medical, Inc (SILK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
52.97+1.67 (+3.26%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close51.30
Bid44.55 x 1100
Ask64.00 x 800
Day's Range51.19 - 53.21
52 Week Range33.71 - 75.80
Avg. Volume346,824
Market Cap1.82B
Beta (5Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)-1.44
Earnings DateApr 28, 2021 - May 03, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est67.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Silk Road Medical Appoints William Hill as General Counsel

    Silk Road Medical Appoints William Hill as General Counsel

    SUNNYVALE, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the appointment of William Hill as General Counsel. The veteran corporate executive joins the company to oversee all risk management and legal matters, reporting directly to President and Chief Executive Officer, Erica Rogers. “As we continue to usher in a new era of transcarotid therapies, we look forward to benefitting from Bill’s knowledge on a broad range of legal matters in healthcare and the regulated environment in which we operate,” said Erica Rogers. Prior to joining Silk Road Medical, Mr. Hill served as General Counsel for Natus Medical Incorporated for over 14 years. He was responsible for managing a broad range of global legal issues, including corporate-wide liability mitigation and international legal compliance strategies, mergers and acquisitions, general commercial law and litigation, and employment law. Mr. Hill began his legal career in the mass tort department at Porzio, Bromberg, & Newman P.C. in New Jersey where he assisted with product liability, FDA, and pharmaceutical litigation matters. He has also performed pro bono legal work for the Pro Bono Project of Silicon Valley supporting underrepresented communities in family law cases. Mr. Hill graduated from the University of Maryland School of Law where he served as a summer clerk at the United States District Court. He completed his undergraduate education at the University of North Carolina at Chapel Hill. About Silk Road Medical Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook. Investors:Media:Lynn Lewis or Caroline PaulMichael FanucchiGilmartin GroupSilk Road Medicalinvestors@silkroadmed.commfanucchi@silkroadmed.com

  • Is It Too Late to Buy Silk Road Medical (SILK) Stock?
    Insider Monkey

    Is It Too Late to Buy Silk Road Medical (SILK) Stock?

    Wasatch Small Cap Growth Fund recently released its Q4 2020 Investor Letter, a copy of which you can download here. The fund posted a return of 29.7% for the quarter, in line with its benchmark, the Russell 2,000 Growth Index which returned 29.6% in the same quarter. You should check out Wasatch’s top 5 stock […]

  • New Strong Sell Stocks for March 25th

    New Strong Sell Stocks for March 25th

    APG, FLR, ROCK, SILK, and CYD have been added to the Zacks Rank #5 (Strong Sell) List on March 25, 2021